Note 6 - Significant Alliances and Related Parties

3 Months Ended

Mar. 31, 2020

Notes to Financial Statements

Related Party Transactions Disclosure [Text Block]

6.

 Significant Alliances and Related Parties

Roswell Park Cancer Institute

The Company has entered into several agreements with Roswell Park Cancer Institute ("

RPCI

"), including: various sponsored research agreements, an exclusive license agreement and clinical trial agreements for the conduct of the Phase

1

entolimod oncology study and the Phase

1

Curaxin

CBL0137

("

Curaxin

") intravenous administration study. Additionally, the Company’s Chief Scientific Officer, or CSO, Dr. Andrei Gudkov, is the Senior Vice President of Research Technology and Innovation at RPCI. The Company incurred

$1,197

and

$0

 in research and development expense to RPCI for the

three

months ended

March 31, 2020

 and

2019,

respectively. 

The Cleveland Clinic

CBLI has entered into an exclusive license agreement with The Cleveland Clinic pursuant to which CBLI was granted an exclusive license to The Cleveland Clinic’s research base underlying our therapeutic platform and certain product candidates licensed to Panacela. CBLI has the primary responsibility to fund all newly developed patents. However, The Cleveland Clinic retains ownership of those patents covered by the agreement. CBLI also agreed to use commercially diligent efforts to bring

one

or more products to market as soon as practical, consistent with sound and reasonable business practices and judgments. On

August 6, 2018,

CBLI sublicensed the intellectual property underlying entolimod's composition that CBLI licenses from The Cleveland Clinic to GPI. There were

no

milestone or royalty payments paid to The Cleveland Clinic during the 

three

months ended

March 31, 2020

or

2019

.

The Company incurred

$0

and

$30,710

in research and development expense to The Cleveland Clinic during the

three

months ended

March 31, 2020

and

2019

, respectively.

Buffalo BioLabs and Incuron

Our CSO, Dr. Andrei Gudkov, has business relationships with Buffalo BioLabs, LLC ("

BBL

"), where Dr. Gudkov was a founder and currently serves as its uncompensated Principal Scientific Advisor. The Company recognized

no

research and development expense to BBL for the

three

months ended

March 31, 2020

 and

2019,

respectively. The Company also recognized

$0

and

$11,553

from BBL as sublease and other income for the

three

months ended

March 31, 2020

and

2019

, respectively. Pursuant to our real estate sublease and equipment lease with BBL, the Company had gross accounts receivables of

$6,285

and

$222,938,

and net accounts receivables of

$6,285

and

$20,787

from BBL at

March 31, 2020

and

2019

, respectively.

Dr. Gudkov is also an uncompensated member of the board of directors for Incuron. Pursuant to master service and development agreements we have with Incuron, the Company performs various research, business development, clinical advisory, and management services for Incuron. The Company recognized revenue of

$41,010

and

$134,067

for the

three

months ended

March 31, 2020

 and

2019,

respectively. In addition, we also recognized

$0

and

$1,134

from Incuron for sublease and other income for the

three

months ended

March 31, 2020

 and

2019,

respectively. Pursuant to these agreements, the Company had gross accounts receivable of

$140,595

and

$134,823

from Incuron at

March 31, 2020

and

2019

, respectively.

Genome Protection

GPI incurred

$13,440

and

$47,425

in consultant expenses with members of the Company's Board of Directors and management team during the

three

months ended

March 31, 2020

 and

2019,

respectively. The Company also recognized

$0

and

$3,031

 in sublease and other income from GPI during the

three

months ended

March 31, 2020

 and

2019,

respectively.